TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38842764
Drug: Dexketoprofen monotherapy
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen monotherapy
Study: 38842838
Drug: Neoadjuvant nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant nivolumab plus chemotherapy (nab-paclitaxel and carboplatin) followed by response-adapted locoregional therapy (LRT)
Study: 38842838
Drug: Response-adapted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-adapted therapy (group A: single-modality radiotherapy or transoral robotic surgery; group B: intermediate-dose chemoradiotherapy; group C: regular-dose chemoradiotherapy)
Study: 38842838
Drug: Neoadjuvant nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant nivolumab and chemotherapy followed by response-adapted LRT
Study: 38842850
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention (cognitive behavior therapy for psychosis strategies)
Study: 38843038
Drug: Clusters based
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clusters based on within-treatment symptom trajectories
Study: 38843105
Drug: Bexotegrast, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexotegrast, dosage and duration not available
Study: 38843267
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg H1N1 influenza vaccine
Study: 38843267
Drug: 7.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg H1N1 influenza vaccine
Study: 38843267
Drug: Both VX-103
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both VX-103 dose groups
Study: 38843272
Drug: pool-REST (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: pool-REST (weekly 1-hour float sessions)
Study: 38843272
Drug: chair-REST (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: chair-REST (weekly 1-hour sessions in a Zero Gravity chair)
Study: 38843355
Drug: Ivosidenib (anti-IDH1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivosidenib (anti-IDH1 therapy)
Study: 38843469
Drug: G/C
Normalized name: GG/Codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: G/C
Study: 38843511
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) - 10 mg/kg intravenous infusion on days 1 and 8
Study: 38843511
Drug: Docetaxel -
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel - 75 mg/m²
Study: 38843604
Drug: Patients evaluated
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients evaluated twice (4 months and 16 months)
Study: 38843860
Drug: Vimseltinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vimseltinib (30 mg orally twice weekly for 24 weeks)
Study: 38843950
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) administered into the large intestine (LI)
Study: 38843950
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) administered into the small intestine (SI)
Study: 38843950
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplantation (FMT) administered into the small intestine (SI) twice (repeated SI)
Study: 38844374
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 µg thrice daily for 2 months
Study: 38844406
Drug: Blinatumomab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (5 μg/m²)
Study: 38844468
Drug: penpulimab and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: penpulimab and anlotinib in combination with nab-paclitaxel/gemcitabine (PAAG)
Study: 38844796
Drug: Precision-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision-guided treatment (PGT)
Study: 38844798
Drug: Calibrated blood-collection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calibrated blood-collection drape for early detection of PPH and bundled first-response treatments (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination and escalation)
Study: 38844862
Drug: Maraviroc 300
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300 mg daily for 10 weeks
Study: 38844921
Drug: Dual systemic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual systemic anti-pseudomonal antibiotics for 14 days
Study: 38845045
Drug: VHW-led lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: VHW-led lifestyle counseling and guideline-directed antihypertensive, lipid-lowering, and antiplatelet treatment supported by a tablet-based decision support application in intervention villages.
Study: 38845046
Drug: PF-06835375 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06835375 (dose range: 0.03-6 mg) - single doses administered intravenously
Study: 38845046
Drug: PF-06835375 (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06835375 (dose range: 0.3-10 mg) - repeat doses administered subcutaneously on Days 1 and 29
Study: 38845164
Drug: FIT cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT cut-off 20 µg/g
Study: 38845164
Drug: FIT cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT cut-off 40 µg/g
Study: 38845164
Drug: FIT cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT cut-off 10 µg/g
Study: 38845164
Drug: FIT cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT cut-off 20 µg/g (men)
Study: 38845164
Drug: FIT cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT cut-off 20 µg/g (women)
Study: 38845288
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment of traditional cardiovascular risk factors
Study: 38846711
Drug: Glucose-lowering medications
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-lowering medications
Study: 38847460
Drug: Survodutide 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide 6.0 mg
Study: 38848312
Drug: Bivalent mRNA
Normalized name: Adult B and BA.4/BA.5 lineage SARS-CoV-2 bivalent mRNA only vaccine product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2)
Study: 38848380
Drug: Pharmacist-led interprofessional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led interprofessional medication adherence program (IMAP) for 12 months
Study: 38848477
Drug: Nirmatrelvir-ritonavir (NMV/r,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirmatrelvir-ritonavir (NMV/r, 300 mg and 100 mg)
Study: 38848522
Drug: Intravenous clemastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clemastine
Study: 38848557
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 2 daily messages unrelated to smoking.
Study: 38849054
Drug: Repeated low-level
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated low-level red light therapy (RLRL) plus single-vision spectacles
Study: 38849054
Drug: Repeated low-level
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated low-level red light therapy (RLRL)
Study: 38849152
Drug: tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 5 mg two times per day or equivalent weight-based doses
Study: 38849726
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy and PARP inhibitors
Study: 38849734
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous ibuprofen 800 mg
Study: 38849875
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg capsule 1-2 hours before surgery
Study: 38849943
Drug: Lomustine (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomustine (110 mg/m2)
Study: 38850311
Drug: Gallium-68-labeled FAP
Normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallium-68-labeled FAP inhibitor 04
Study: 38850402
Drug: Adjunctive cenobamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive cenobamate
Study: 38851166
Drug: MK-8189 12
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8189 12 mg
Study: 38851166
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg (active control)
Study: 38851203
Drug: First-line treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatment (specific intervention details not provided)
Study: 38851207
Drug: Ramucirumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (10 mg/kg intravenously) and Pembrolizumab (200 mg intravenously)
Study: 38851225
Drug: Malkia Klabu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malkia Klabu (Queen Club) intervention at ADDOs providing free contraceptives and oral HIV self-test kits, with a customer loyalty programme.
Study: 38851232
Drug: Vivomixx (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vivomixx (450 billion colony-forming units per sachet) taken once daily until 1 week postpartum
Study: 38851232
Drug: Placebo taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken once daily until 1 week postpartum
Study: 38851233
Drug: Continuous glucose
Normalized name: sub-q infusion pump w/continuous glucose monitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous glucose monitoring and oral glucose tolerance testing
Study: 38851462
Drug: Nemonoxacin 500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 500 mg IV once daily for 7-14 days
Study: 38851462
Drug: Levofloxacin IV
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin IV once daily for 7-14 days
Study: 38851666
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of hypnotics without a previous etiological diagnosis
Study: 38851676
Drug: 3D-printed mandibular
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D-printed mandibular implant overdenture
Study: 38851710
Drug: Directional atherectomy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directional atherectomy plus drug-coated balloon (DCB)
Study: 38852114
Drug: Oral FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral FTC/TDF
Study: 38852379
Drug: Palbociclib in
Normalized name: Product containing palbociclib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib in combination with endocrine therapy (letrozole or fulvestrant)
Study: 38852601
Drug: Neoadjuvant camrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant camrelizumab (200 mg IV on day 1) plus apatinib (250 mg orally from day 1-14, every 3 weeks for 3 months)
Study: 38852675
Drug: Upfront primary
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront primary tumor resection (PTR) followed by systemic therapy
Study: 38852675
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy without upfront PTR
Study: 38852760
Drug: Acamprosate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate treatment for three months
Study: 38852770
Drug: ASMD trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASMD trial patients (before exposure to treatment)
Study: 38853265
Drug: Tislelizumab combined
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab combined with chemotherapy (albumin-bound paclitaxel and carboplatin) for up to four cycles
Study: 38853265
Drug: Tislelizumab combined
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab combined with chemotherapy
Study: 38853269
Drug: Multi-ingredient pre-workout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-ingredient pre-workout dietary supplement (MIPS)
Study: 38853394
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg twice daily and Amoxicillin 750 mg four times daily (TA group)
Study: 38853394
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg and Amoxicillin 750 mg four times daily (EA group)
Study: 38853420
Drug: Pre-hospital fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital fluid therapy (Intervention)
Study: 38853420
Drug: Pre-hospital fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital fluid therapy (Control)
Study: 38853689
Drug: oHSV therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: oHSV therapy (rQNestin34.5v.2)
Study: 38853958
Drug: Morning Bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning Bright Light Therapy (MBLT); n=80; 60-min duration; daily over 28-day duration.
Study: 38853958
Drug: Sham: deactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham: deactivated negative ion generator; n=40; 60-min duration; daily over 28-day duration.
Study: 38854091
Drug: Celecoxib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100 mg every 12h)
Study: 38854091
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 mg every 12h)
Study: 38854392
Drug: Ensovibep (75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensovibep (75, 225, or 600 mg)
Study: 38854853
Drug: Standard Tablet
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Tablet (Control)
Study: 38854963
Drug: Submaximal balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Submaximal balloon angioplasty (SBA) combined with standard medical therapy
Study: 38855751
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Atorvastatin (80 mg) once daily
Study: 38855751
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Placebo once daily
Study: 38856026
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg and 300 mg)
Study: 38856863
Drug: BAY 3375968
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 3375968 (anti-human CCR8 antibody)
Study: 38856863
Drug: BAY 3375968
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 3375968 (anti-human CCR8 antibody) in combination with immune checkpoint inhibitors (ICIs)
Study: 38856885
Drug: Novel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatment planning process focused on shared decision-making (SDM)
Study: 38856885
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment planning process
Study: 38857015
Drug: Aggressive antipyretic
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aggressive antipyretic therapy (acetaminophen 30 mg/kg load, then 15 mg/kg plus ibuprofen 10 mg/kg every 6 hours for 72 hours)
Study: 38857015
Drug: Aggressive antipyretic
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aggressive antipyretic therapy
Study: 38857015
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (15 mg/kg of acetaminophen as needed every 6 hours for temperature of 38.5 °C or higher)
Study: 38857463
Drug: Subcutaneous amivantamab-lazertinib
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous amivantamab-lazertinib
Study: 38857463
Drug: Intravenous amivantamab-lazertinib
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous amivantamab-lazertinib
Study: 38857509
Drug: Individualized opioid-prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized opioid-prescription protocol (IOPP) with shared decision making
Study: 38857509
Drug: Fixed quantity
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed quantity (20 tablets of 5 mg oxycodone)
Study: 38857611
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg orally per day) plus usual care
Study: 38857611
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg orally per day)
Study: 38857788
Drug: Survodutide 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Survodutide 0.3 mg (single subcutaneous dose)
Study: 38857986
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of T-MACS estimates and CTCA findings
Study: 38858103
Drug: mirvetuximab soravtansine-gynx
Normalized name: mirvetuximab soravtansine-gynx
DrugBank: Mirvetuximab soravtansine (DB12489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirvetuximab soravtansine-gynx 6 mg/kg IV every 3 weeks until progression or unacceptable toxicity
Study: 38858106
Drug: Tiragolumab plus
Normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab plus atezolizumab (tiragolumab 600 mg + atezolizumab 1200 mg every 3 weeks)
Study: 38858106
Drug: Atezolizumab alone
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab alone (1200 mg every 3 weeks)
Study: 38858145
Drug: SABA prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA prescriptions (≥3 SABA canisters/year)
Study: 38858145
Drug: SABA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: SABA in addition to maintenance therapy
Study: 38858147
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard antiplatelet therapy)
Study: 38858161
Drug: Venoarterial ECMO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoarterial ECMO treatment
Study: 38858375
Drug: Mobile game
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile game therapy intervention for ADHD, 4-week home-based game intervention.
Study: 38858523
Drug: Retatrutide 8
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 8 mg
Study: 38858523
Drug: Retatrutide 12
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 12 mg
Study: 38858629
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual + Mindfulness (TaU + MIND)
Study: 38858721
Drug: Pre-treatment peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment peripheral blood myeloid cells in TNBC
Study: 38858721
Drug: Pre-treatment CD8+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment CD8+ naive T cells and CD4+ effector memory cells re-expressing CD45RA in hormone receptor-positive breast cancer
Study: 38858818
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 or 20 mg depending on eGFR above or below 60 mL/min/1.73 m2
Study: 38859644
Drug: Reduced-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose edoxaban (30 mg)
Study: 38859744
Drug: Erenumab treatment
Normalized name: erenumab
DrugBank: Erenumab (DB14039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Erenumab treatment
Study: 38859883
Drug: Intravenous odatroltide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous odatroltide (0.025 mg/kg)
Study: 38860025
Drug: TDF/FTC PrEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC PrEP (two, four, or seven doses per week for 8 weeks)
Study: 38860025
Drug: TDF/FTC PrEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC PrEP (seven doses per week for 8 weeks)
Study: 38860394
Drug: Higher lipoprotein(a)
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher lipoprotein(a) ≥150 nmol/L
Study: 38860727
Drug: Progressive exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive exercise therapy (PR)
Study: 38860901
Drug: Vortioxetine (detailed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (detailed dosage and duration not specified)
Study: 38861324
Drug: Individualized anemia
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized anemia therapy
Study: 38861659
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavior therapy (bCBT)
Study: 38861707
Drug: POSSIBLE intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: POSSIBLE intervention using the PrEPme app and peer change agent (PCA)
Study: 38861793
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium (shake containing 700 mg Ca/day)
Study: 38861793
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium (shake with 6.4 mg Ca/day)
Study: 38861793
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups on energy-restricted diets (-500 kcal/d, 800 mg of dietary Ca/d)
Study: 38862179
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (ticagrelor 90 mg twice daily plus aspirin 100 mg once daily)
Study: 38862179
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy (90 mg twice daily)